focus -WSS

focus

author：leisure time 2025-08-11 05:32:34 - browse：13

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Belarusian journalist sentenced to 4 years in prison as crackdown continues

focus

WSS

GOP inquiry over gain

Belarusian journalist sentenced to 4 years in prison as crackdown continues

UnitedHealth wins $3.3 billion takeover of Amedisys

Some top drug companies are starting to take action on climate

GOP inquiry over gain

The simple reason for the increase in autism diagnosis

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Experts study whether long Covid risk adds up with each reinfection

Trump demands the U.S. pay no more for drugs than other countries … again

6 solutions to address cancer drug shortages and others

In Memoriam: Notable people who died in 2023

Some top drug companies are starting to take action on climate

State Dept. review finds Biden bears some blame for Afghanistan failures

Study points to new risk in gene therapy death of Terry Horgan

United colonoscopy coverage change 'may cost lives,' doctors say

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

explore

CRISPR base editing slashes cholesterol levels in monkeys

Synthetic human embryos? Researchers say term is overblown

Some top drug companies are starting to take action on climate

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Belarusian journalist sentenced to 4 years in prison as crackdown continues

leisure time

hotspot

focus

entertainment